a

Trulicity vs Mounjaro: Are They the Same Medication?

Trulicity vs Mounjaro: Are They the Same Medication?

Trulicity and Mounjaro are two different medicines used to control blood sugar levels. Trulicity is a weekly injection that helps your body manage blood sugar like it’s supposed to. It was approved by the FDA in 2014 and has been shown to help prevent serious heart problems.

Mounjaro, on the other hand, is a newer medicine called tirzepatide.

It works in two ways to control blood sugar and also helps with weight loss. The FDA approved it in 2022.

Understanding how these medicines work and what they can do is important because it helps doctors and patients make informed decisions about the best treatment for type 2 diabetes.

Composition and Mechanism of Action

Trulicity (Dulaglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1 (7-37) covalently linked to an Fc fragment of human IgG4. Its chemical formula is C2646H4044N704O836S18 with a molar mass of 59,670.63 g/mol. Trulicity is administered subcutaneously once a week.

Mounjaro (Tirzepatide) is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist.

It is a synthetic peptide with a sequence of amino acids designed to mimic the incretin hormones GLP-1 and GIP. Mounjaro is also administered subcutaneously, typically once a week.

Mechanisms of Action:

  • Trulicity: Trulicity activates GLP-1 receptors, leading to increased insulin secretion in a glucose-dependent manner and decreased glucagon secretion. It also slows gastric emptying and reduces appetite, which can contribute to weight loss.

  • Mounjaro: Mounjaro activates both GLP-1 and GIP receptors, enhancing insulin secretion and inhibiting glucagon secretion more effectively than GLP-1 agonists alone.

    It also slows gastric emptying and reduces appetite, contributing to weight loss.

Similarities:

  • Both medications are GLP-1 receptor agonists and are used to improve glycemic control in adults with type 2 diabetes.

  • Both medications are administered subcutaneously once a week and can lead to weight loss due to slowed gastric emptying and reduced appetite.

Differences:

  • Trulicity is a GLP-1 agonist only, while Mounjaro is a dual GLP-1 and GIP agonist.

  • Mounjaro may offer additional benefits over Trulicity due to its dual action on both GLP-1 and GIP receptors, potentially leading to greater improvements in glycemic control and weight loss.

These differences in mechanisms of action contribute to their therapeutic outcomes, with Mounjaro potentially providing a more robust approach to managing type 2 diabetes and associated weight loss.

Indications and Usage

Trulicity (dulaglutide) is prescribed for adults with type 2 diabetes to help manage blood sugar levels and reduce the risk of cardiovascular events in those with heart disease. It works by stimulating insulin release, slowing digestion, and reducing liver glucose production.

Mounjaro (tirzepatide) is also used for adults with type 2 diabetes to lower blood sugar levels. It activates GLP-1 and GIP receptors, increasing incretin hormones, enhancing insulin production, and slowing digestion.

Additionally, Mounjaro is prescribed for weight loss in individuals with obesity or overweight conditions related to health issues.

While both medications are used to manage type 2 diabetes, Mounjaro has the added indication for weight loss, making it distinct from Trulicity. They are not used interchangeably but rather chosen based on individual patient needs and specific medical conditions.

Side Effects and Safety Profiles

Trulicity (dulaglutide) and Mounjaro (tirzepatide) are both GLP-1 receptor agonists used to treat type 2 diabetes, but they have different side effects and safety profiles.

Trulicity (dulaglutide)

Common Adverse Reactions:

  • Nausea and vomiting

  • Diarrhea

  • Stomach pain

  • Decreased appetite

  • Indigestion

  • Fatigue

  • Injection site reactions

Severe Risks:

  • Pancreatitis (inflammation of the pancreas)

  • Kidney damage

  • Gallbladder disease

  • Thyroid tumors (in animal studies)

  • Severe allergic reactions

Overall Safety Considerations:

  • Trulicity can cause low blood glucose levels, especially when combined with other diabetes medications.

  • It is contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

  • Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with dulaglutide.

Mounjaro (tirzepatide)

Common Adverse Reactions:

  • Nausea and vomiting

  • Diarrhea

  • Constipation

  • Abdominal pain

  • Decreased appetite

  • Heartburn

  • Burping

  • Injection site reactions

Severe Risks:

  • Pancreatitis (inflammation of the pancreas)

  • Hypoglycemia (low blood sugar), especially when used with other diabetes medications

  • Gallbladder disease

  • Kidney problems (dehydration resulting from gastrointestinal side effects can lead to kidney issues)

  • Thyroid tumors (in animal studies)

Overall Safety Considerations:

  • Mounjaro has a boxed warning for the risk of thyroid tumors based on animal studies.

  • It is contraindicated in patients with a history of MTC or MEN 2.

  • Caution is advised in patients with gallbladder disease.

Both medications have similar common side effects, but the severe risks and overall safety considerations differ slightly. It’s important to discuss these with a healthcare provider to determine the best treatment option based on individual health needs and medical history.

Efficacy and Patient Outcomes

Trulicity (dulaglutide) and Mounjaro (tirzepatide) are both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used to manage type 2 diabetes. Clinical trials have shown that both medications are effective in lowering A1C levels, but there are some differences in their efficacy, patient satisfaction, and long-term benefits.

Efficacy

  • Trulicity: Clinical trials, such as the REWIND trial, have demonstrated that Trulicity can reduce major cardiovascular events by 12% and significantly lower A1C levels from baseline. The AWARD-11 trial showed that Trulicity also led to weight reduction.

  • Mounjaro: The SURPASS program, which included five global clinical trials, showed that Mounjaro was superior to placebo in reducing A1C levels and led to greater reductions in body weight compared to Trulicity.

    Mounjaro also achieved A1C and weight targets in less time than injectable semaglutide.

Patient Satisfaction

  • Trulicity: Patient satisfaction with Trulicity has been generally positive, with many patients reporting improved glycemic control and weight management.

  • Mounjaro: Patient satisfaction with Mounjaro has been high, with many patients experiencing significant weight loss and improved glycemic control. The rapid achievement of A1C and weight targets has contributed to higher patient satisfaction.

Long-term Benefits

  • Trulicity: Long-term benefits of Trulicity include sustained reductions in cardiovascular events and A1C levels. The consistent reduction in cardiovascular risk has been maintained throughout the study period.

  • Mounjaro: Long-term benefits of Mounjaro include sustained weight loss and improved glycemic control.

    The mechanism of action study showed that Mounjaro led to greater reductions in weight and fat mass compared to Trulicity.

In summary, both Trulicity and Mounjaro are effective in managing type 2 diabetes, but Mounjaro has shown superior efficacy in terms of A1C reduction and weight loss. Patient satisfaction is high for both medications, but Mounjaro’s rapid achievement of targets has contributed to higher satisfaction. Long-term benefits for both medications include sustained improvements in glycemic control and cardiovascular outcomes, with Mounjaro showing greater weight loss benefits.

Cost and Accessibility

Trulicity (dulaglutide) is priced at around $1,023 to $1,135 per month for a monthly supply of four weekly injection pens. The cost can vary depending on the pharmacy, dosage, and location. Insurance coverage for Trulicity can differ based on the plan, and prior authorization may be required.

Patients can also access financial assistance through the Lilly Cares Foundation, which offers a Patient Assistance Program.

Mounjaro (tirzepatide) costs approximately $1,023 to $1,135 per month for a monthly supply of four weekly injection pens. Similar to Trulicity, the price can vary based on the pharmacy, dosage, and location. Insurance coverage for Mounjaro also varies, and patients may need prior authorization.

Eli Lilly provides a savings card for eligible patients, which can reduce the cost to as little as $25 per month with a maximum savings of $150 per 28-day supply.

Both medications have financial assistance programs available to help reduce the cost for patients. Patients should consult their healthcare provider or pharmacist for more information on insurance coverage and financial assistance options.

Comparing Trulicity (dulaglutide) and Mounjaro (tirzepatide)

Trulicity (dulaglutide) and Mounjaro (tirzepatide) are both effective in managing type 2 diabetes, but they have distinct differences in efficacy, patient satisfaction, and long-term benefits. Clinical trials have shown that Mounjaro is superior to Trulicity in reducing A1C levels and leading to greater weight loss. Patient satisfaction with Mounjaro has been high due to its rapid achievement of targets, while Trulicity has generally positive patient satisfaction ratings.

Safety Comparison

In terms of safety, both medications have similar common side effects, but the severe risks differ slightly. Trulicity is contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), while Mounjaro has warnings for the risk of thyroid tumors based on animal studies.

Cost Comparison

The cost of both medications is similar, ranging from $1,023 to $1,135 per month for a monthly supply of four weekly injection pens. However, insurance coverage and financial assistance programs can vary, with Trulicity offering a Patient Assistance Program through the Lilly Cares Foundation and Mounjaro providing a savings card that can reduce the cost to as little as $25 per month.

Conclusion

In conclusion, while both medications are effective in managing type 2 diabetes, significant differences exist between Trulicity and Mounjaro. Mounjaro’s superior efficacy in reducing A1C levels and leading to greater weight loss make it a more attractive option for patients seeking rapid improvements in glycemic control and weight management.

Practical Advice

  1. Patients should discuss their individual health needs and medical history with their healthcare provider to determine the best treatment option.
  2. Healthcare providers should consider the patient’s specific goals, such as A1C reduction or weight loss, when selecting a medication.
  3. Patients should inquire about insurance coverage and financial assistance programs available for both medications.
  4. Regular monitoring of glycemic control, weight, and potential side effects is essential to ensure safe and effective treatment.

Comments

    Leave a Reply

    Your email address will not be published. Required fields are marked *